publication venue for
- A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα).. 23. 2021
- A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis.. 22. 2020
- Contrast-Enhanced Mammography and Radiomics Analysis for Noninvasive Breast Cancer Characterization: Initial Results.. 22. 2020
- The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides.. 22. 2020
- Impact of Tissue Classification in MRI-Guided Attenuation Correction on Whole-Body Patlak PET/MRI.. 21. 2019
- Glucose-6-phosphatase Expression-Mediated [18F]FDG Efflux in Murine Inflammation and Cancer Models.. 21. 2019
- Adenine Nucleotide Translocase 2 as an Enzyme Related to [18F] FDG Accumulation in Various Cancers.. 21. 2019
- Quantitative Analysis of Heterogeneous [18F]FDG Static (SUV) vs. Patlak (Ki) Whole-body PET Imaging Using Different Segmentation Methods: a Simulation Study.. 21. 2019
- Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.. 20. 2018
- Erratum to: Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.. 19. 2017
- In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.. 19. 2017
- Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.. 19. 2017
- Detection of Lymph Node Metastases with SERRS Nanoparticles.. 18. 2016
- Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.. 18. 2016
- Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.. 15. 2013
- Tumor-specific targeting with modified Sindbis viral vectors: evaluation with optical imaging and positron emission tomography in vivo.. 15. 2013
- Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer.. 14. 2012
- Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.. 14. 2012
- Labeling human mesenchymal stem cells with fluorescent contrast agents: the biological impact.. 13. 2011
- Plasma protein binding of luciferase substrates influences sensitivity and accuracy of bioluminescence imaging.. 13. 2011
- Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.. 8. 2006
- Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus.. 8. 2006
- Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients.. 7. 2005
- Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease.. 6. 2004
- Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients.. 5. 2003
- Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.. 5. 2003
- A patient with primary cardiac lymphoma.. 4. 2002
- Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tübingen, Germany. 2015
- Precision Medicine…Visualized-a Message from the President of the WMIC.. 17. 2015
- Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. 2007
- Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development. 2005